Sugi Predict

Sugi Predict / Compounds / SCHEMBL6131409

SCHEMBL6131409

SCHEMBL6131409

CC(C)c1cccc(Nc2ccccc2C=O)c1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ LMNA P02545 3/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ BLM P54132 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ TSHR P16473 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LPAR1 Q92633 1/20 0.34
▸ CXCL8 P10145 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ FAAH O00519 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6131394 0.84 LMNA (0.41) L3MBTL1CYP2C9CYP2C19LMNAKMT2A
SCHEMBL5473286 0.79 LMNA (0.42) LMNAKMT2ABLMMEN1THRB
SCHEMBL29472311 0.79 LMNA (0.42) LMNAKMT2ABLMMEN1THRB
SCHEMBL4333864 0.77 LMNA (0.60) CYP2C9CYP2C19LMNAKMT2ABLM
SCHEMBL30594030 0.75 KMT2A (0.48) L3MBTL1CYP2C9CYP2C19LMNAKMT2A
SCHEMBL385724 0.73 LMNA (0.55) L3MBTL1CYP2C9CYP2C19LMNAKMT2A
SCHEMBL14306858 0.73 ALDH1A1 (0.47) CYP2C9CYP2C19LMNAKMT2ABLM
SCHEMBL28644100 0.72 LMNA (0.52) L3MBTL1LMNAKMT2ABLMMEN1
SCHEMBL10695412 0.71 ALDH1A1 (0.59) L3MBTL1CYP2C9CYP2C19LMNAKMT2A
SCHEMBL7341065 0.70 LMNA (0.54) CYP2C9CYP2C19LMNAKMT2ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974878-B2 Catalyst ligands, catalytic metal complexes and processes using same SYMYX TECHNOLOGIES, INC. (US) 2005-12-13 — — US disclosed
US-20040249157-A1 Catalyst ligands, catalytic metal complexes and processes using same SYMYX TECHNOLOGIES, INC. 2004-12-09 — — US disclosed
US-20040242881-A1 Catalyst ligands, catalytic metal complexes and processes using same SYMYX TECHNOLOGIES, INC. 2004-12-02 — — US disclosed
US-20020137934-A1 Catalyst ligands, catalytic metal complexes and processes using and methods of making same SYMYX TECHNOLOGIES 2002-09-26 — — US disclosed
US-6316663-B1 CATALYTIC ADDITION POLYMERIZATION OF OLEFINS, DIOLEFINS, AND/OR ACETYLENIC COMPOUNDS SYMYX TECHNOLOGIES, INC. 2001-11-13 — — US disclosed
EP-1131283-A1 CATALYST LIGANDS, CATALYTIC METAL COMPLEXES AND PROCESSES USING AND METHODS OF MAKING SAME SYMYX TECHNOLOGIES (US) 2001-09-12 — — EP disclosed
WO-2001019786-A1 CATALYST LIGANDS, CATALYTIC METAL COMPLEXES AND PROCESSES USING AND METHODS OF MAKING SAME SYMYX TECHNOLOGIES (US) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249157-A1 Catalyst ligands, catalytic metal complexes and processes using same SOD1, OSTC, ZC3HAV1L L3MBTL1 3577/4885CYP2C9 1084/4885CYP2C19 1029/4885
US-20040242881-A1 Catalyst ligands, catalytic metal complexes and processes using same SOD1, OSTC, ZC3HAV1L L3MBTL1 3577/4885CYP2C9 1084/4885CYP2C19 1029/4885
US-20020137934-A1 Catalyst ligands, catalytic metal complexes and processes using and methods of making same SOD1, ZC3HAV1L, OSTC L3MBTL1 3960/4885CYP2C9 766/4885CYP2C19 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.